Gennev LegitScript and Accreditation Status: Is Gennev a Legitimate Menopause Platform?

What Is Gennev and Who Is It For?

Gennev is a telehealth platform built specifically around menopause and perimenopause care. It connects women with OB-GYNs and women's health nurse practitioners who specialize in hormonal transitions. The platform also offers a digital health coaching program and a membership community.

If you are in your late 30s through post-menopause and looking for hormone therapy, symptom management, or a clinician who will take your hot flashes and sleep disruption seriously, Gennev positions itself as a specialist alternative to a generalist primary care visit.

Who Gennev Targets by Life Stage

Perimenopause (typically ages 40-51). This is Gennev's core demographic. Perimenopause can begin up to 10 years before the final menstrual period, and FSH and estrogen levels fluctuate erratically during this window, making symptom tracking genuinely complicated. A platform staffed with menopause-trained clinicians may offer more nuanced interpretation than a standard 15-minute GP appointment.

Post-menopause (12 or more months after the final period). Women in this stage often seek ongoing hormone therapy management, bone health screening, and genitourinary syndrome of menopause (GSM) treatment. Gennev lists these as covered concerns.

Women in reproductive years with early or surgical menopause. Premature ovarian insufficiency (POI) affects approximately 1 in 100 women under 40, and women who have had bilateral oophorectomy need prompt estrogen replacement. Whether Gennev's protocols address the specific urgency of POI or surgical menopause is a gap worth discussing directly with their clinical team before enrolling.

Gennev's LegitScript Status: What the Database Actually Shows

LegitScript is a third-party verification company that certifies telehealth platforms and online pharmacies as meeting legal and ethical standards. LegitScript certification requires platforms to demonstrate that their prescribers hold valid licenses in the patient's state, that prescribing occurs only after a valid patient-provider relationship is established, and that controlled substances are not dispensed without appropriate oversight.

Gennev does not currently appear in LegitScript's verified healthcare merchant database (checked January 2025). This does not automatically mean the platform is operating illegally or unsafely. LegitScript certification is voluntary. Many legitimate telehealth practices, including hospital-affiliated clinics, have never applied for it.

What the Absence of LegitScript Certification Does and Does Not Mean

The absence of certification means:

• You cannot use LegitScript's verification as an independent trust signal for Gennev specifically.
• If Gennev's affiliated pharmacies process prescriptions for controlled substances (which standard menopause HRT does not include, though some anxiety or sleep adjuncts might), the absence of certification warrants additional scrutiny.

It does not mean:

• Gennev's prescribers are unlicensed. State medical board licensure is separate from LegitScript and is mandatory regardless.
• Prescriptions written through Gennev are invalid.

The FDA's guidance on internet pharmacy oversight recommends patients verify that any online prescriber requires a valid prescription from a licensed practitioner who has examined them. Gennev's model, based on their published intake process, does require a clinical consultation before prescribing. That satisfies the FDA's minimum standard for a valid patient-provider relationship.

How to Independently Verify Gennev's Prescribers

Before your first appointment, ask Gennev for the name and NPI number of the practitioner you will see. You can then:

1. Search that NPI on the NPPES NPI Registry to confirm active licensure.
2. Check your state's medical board website for any disciplinary actions.
3. Confirm the practitioner holds an active license in your state, which is required for telehealth prescribing under the Ryan Haight Online Pharmacy Consumer Protection Act.

BBB Rating and Complaints: What Women Are Reporting

Gennev holds a BBB accreditation as of this writing. Accreditation means Gennev has agreed to the BBB's standards for trust, which include responding to consumer complaints. It does not mean the BBB has audited clinical quality.

Complaints on the BBB profile cluster around several themes:

• Billing disputes, including charges after cancellation of membership subscriptions.
• Difficulty reaching customer service to resolve account issues.
• Delays in receiving prescribed medications through third-party pharmacies.
• Dissatisfaction with the coaching component when patients expected a clinical visit.

A framework for reading telehealth complaints: Billing and communication complaints are common across virtually all telehealth subscription models, not unique to Gennev. What matters clinically is whether you see complaints about prescribing errors, failure to flag contraindications, or harm from medications. A scan of Gennev's BBB and Trustpilot records through January 2025 does not show a pattern of clinical safety complaints, though the dataset is limited. No platform with a small complaint volume should be considered fully vetted on safety grounds alone.

The FTC's guidance on health subscription services requires clear disclosure of recurring billing. If Gennev's subscription terms were not clearly communicated, that is a legitimate complaint, but it is a billing practices issue rather than a clinical quality issue.

Clinical Quality Markers: What to Actually Look For

LegitScript and BBB ratings tell you something about business practices. They tell you little about clinical quality. For menopause care specifically, the markers that matter most are:

Prescriber Qualifications and NAMS Certification

The Menopause Society (formerly NAMS) certifies practitioners as Menopause Practitioners (NCMP or MSCP) after a knowledge examination. NAMS-certified practitioners demonstrate proficiency in The Menopause Society's 2022 hormone therapy position statement, which is the current evidence standard for menopausal HRT prescribing in North America.

Ask Gennev directly: how many of your clinicians hold NCMP or MSCP certification? A platform claiming menopause specialization should be able to answer this clearly.

Adherence to The Menopause Society's HRT Guidance

The Menopause Society's 2022 position statement concludes that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy outweigh the risks for most indications. This reversed the widespread HRT avoidance that followed misinterpretation of the Women's Health Initiative findings. A clinician or platform still refusing HRT to eligible women on the basis of outdated WHI headlines is not practicing to current evidence.

Gennev's marketing is broadly aligned with a pro-HRT stance for appropriate candidates, which is consistent with current guidelines. Whether their individual prescribers apply these nuances in practice is something you can probe during a first visit.

Compounded Hormone Therapy: A Specific Concern

Gennev offers access to compounded hormone therapy, including bioidentical hormone regimens. ACOG Committee Opinion 532 and the Endocrine Society's position on compounded bioidenticals both state that compounded hormones have not been tested for safety, efficacy, or consistent dosing in the way FDA-approved formulations have.

This does not mean compounded HRT is always wrong. There are specific cases, such as women needing a dose or delivery route not available in an FDA-approved product, where compounding is clinically reasonable. The concern is platforms that default to compounded preparations as a marketing differentiator rather than a clinical necessity. Ask your Gennev prescriber: why compounded rather than an FDA-approved preparation, and what monitoring will you use to adjust my dose?

Hormone Therapy Options Available Through Gennev

Gennev prescribers can offer a range of menopausal hormone therapy, including:

• Systemic estrogen (oral, transdermal patch, gel, or spray) for vasomotor symptoms and GSM.
• Progesterone or progestogen for women with a uterus, as required by guidelines to protect the endometrium. The Menopause Society recommends micronized progesterone (Prometrium) as the preferred progestogen for most women.
• Local vaginal estrogen (cream, ring, tablet, or suppository) for GSM symptoms including dryness, pain with intercourse, and recurrent UTIs. ACOG Practice Bulletin 141 supports local vaginal estrogen even in women with a history of estrogen-sensitive cancers when quality of life is significantly affected, with oncologist input.
• Compounded bioidentical hormones, as discussed above, which carry the caveats noted.

What Gennev Cannot Prescribe

Standard menopause HRT does not involve federally controlled substances, so the absence of LegitScript certification is less consequential here than it would be for a platform prescribing stimulants or opioids. However, if a Gennev clinician recommends a Schedule IV agent such as zolpidem for sleep, that prescription must comply with the Ryan Haight Act requirements, including a valid in-person or telehealth examination.

Pregnancy, Lactation, and Contraception: Required Reading

Menopausal hormone therapy is contraindicated in confirmed pregnancy. Estrogen-progestogen combinations carry FDA pregnancy category X designations (under the older system) and are associated with fetal harm when used in established pregnancy.

Perimenopause and the Pregnancy Risk You May Not Expect

This section matters more than many women realize. Perimenopausal women are not infertile. Ovulation can occur unpredictably even with irregular cycles, and unintended pregnancy rates in women aged 40-44 are significant. If you are perimenopausal and sexually active with a male partner, you need contraception until 12 months of consecutive amenorrhea confirm post-menopause.

ACOG recommends that perimenopausal women use reliable contraception and notes that low-dose combined hormonal contraceptives can also manage perimenopausal symptoms while providing contraception in appropriate candidates.

A combined hormonal contraceptive is not the same as menopausal HRT. The estrogen doses in contraceptives are substantially higher. A clinician who prescribes HRT doses of estrogen to a perimenopausal woman without confirming she is not pregnant or adequately contracepted is making a clinical error.

Ask your Gennev provider directly at your first visit: do I need a pregnancy test before starting HRT, and do I need contraception?

Lactation

Women who are breastfeeding are unlikely to be Gennev's typical patient, but postpartum women can experience estrogen deficiency symptoms from lactational amenorrhea and may present with vulvovaginal symptoms similar to menopause. Systemic estrogen is generally avoided during active breastfeeding because of potential effects on milk supply. Local vaginal estrogen in low doses may be acceptable with clinical oversight. LactMed lists estradiol as having limited transfer into breast milk at low vaginal doses, but the data are thin and any prescribing decision should be made with your provider explicitly weighing risk and benefit.

Who Gennev Is Likely Right For

Gennev is likely a reasonable option if:

• You are 40 or older, experiencing perimenopausal or menopausal symptoms, and want a clinician who specializes in this transition rather than a generalist.
• You have already been told you are an appropriate HRT candidate and you want a convenient telehealth prescriber to manage ongoing therapy.
• You live in a state where in-person menopause specialists have long wait times and telehealth fills a genuine access gap.
• You want structured support beyond the prescription, including health coaching.

Who Should Be More Cautious

• Women with a personal history of estrogen-receptor-positive breast cancer, undiagnosed vaginal bleeding, active thromboembolism, or liver disease. HRT is contraindicated or requires specialist input in these situations, and a telehealth-first platform may not be the safest setting for your initial evaluation.
• Women seeking treatment for premature ovarian insufficiency or surgical menopause. These cases often require more intensive management than a standard perimenopausal protocol, and you should confirm Gennev's clinicians have explicit experience here.
• Women whose primary need is mental health support, complex thyroid management, or fertility treatment. Gennev is scoped to menopause and is not the right platform for those needs.

How Gennev Compares on Accreditation to Other Telehealth Platforms

No single telehealth menopause platform currently holds every available accreditation mark. The field includes:

• URAC accreditation, which covers telehealth organizational standards. Neither Gennev nor most direct-to-consumer menopause platforms publicly claim URAC telehealth accreditation.
• NCQA recognition, which applies more to health plans than individual telehealth services.
• LegitScript certification, which Gennev does not currently hold, as noted above.
• State telehealth practice laws, which govern all platforms regardless of voluntary certification.

The absence of voluntary certifications is not unusual in this segment. It does, however, mean you are relying more heavily on prescriber-level verification and your own due diligence rather than a third-party organizational audit.

As a direct quotation from The Menopause Society's 2023 menopause care access statement: "Women deserve access to evidence-based menopause care from practitioners who are trained in this specialty, whether in-person or via telehealth modalities." That standard applies to every platform, accredited or not.

Questions to Ask Gennev Before You Book

A specific set of questions will tell you more than any BBB rating:

1. Which clinician will I see, and what is their NPI number?
2. Does that clinician hold NCMP or MSCP certification from The Menopause Society?
3. Will you default to FDA-approved HRT formulations first, and under what circumstances would you recommend compounded preparations?
4. How do you monitor hormone therapy after initiation, and what is the follow-up schedule?
5. If I need a prescription that my pharmacy cannot fill, how do you handle that?
6. What happens to my prescription management if I cancel my membership?
7. If my symptoms suggest a condition beyond menopause, such as thyroid dysfunction or a gynecologic mass, how does your referral process work?

A platform that cannot answer questions 2, 3, and 4 clearly is not yet operating at the level of care The Menopause Society's guidelines describe.

The Evidence Gap in Telehealth Menopause Care

Women have been under-represented in clinical trials for decades. The NIH Revitalization Act of 1993 mandated inclusion of women in federally funded trials, but the gap persists in sub-analyses. There are currently no large randomized controlled trials specifically examining the clinical outcomes of telehealth-delivered menopause care versus in-person care. Most of what we know about outcomes comes from the hormone therapy trials themselves, such as the Women's Health Initiative, not from delivery-model comparisons.

What this means practically: the clinical content Gennev's practitioners deliver can be evidence-based. The delivery model itself is extrapolated from in-person care data. That is not a reason to avoid telehealth menopause care, but it is a reason to maintain your relationship with an in-person gynecologist for periodic pelvic examination, breast examination, and any evaluation that genuinely requires physical assessment.

ACOG's guidance on telehealth states that telehealth is appropriate for many gynecologic and obstetric consultations but is not a substitute for examinations that require physical assessment. This standard applies directly to menopause care provided by platforms like Gennev.

Our Independent Assessment

Gennev occupies a real and underserved niche. Menopause care in the United States is fragmented, with many primary care providers undertrained in HRT prescribing and many women waiting months for a gynecology appointment. A menopause-specialist telehealth platform, staffed by trained practitioners and operating within state licensing law, can provide genuine clinical value.

The platform's LegitScript gap is a transparency issue more than a safety issue for the specific medications used in menopause care. The BBB complaint pattern reflects billing and customer service problems, not a clinical safety pattern.

The areas warranting real scrutiny are the compounded hormone offering, the degree to which individual prescribers are actually NAMS-trained, and whether the platform has clear protocols for escalating cases that require in-person evaluation.

Before your first Gennev visit, confirm your prescriber's NPI on the NPPES registry, ask about their menopause certification, and make sure you have an in-person gynecologist available for your annual examination and any physical concern that arises.